Company intelligence / Profile preview

SciFluor Life Sciences

Boston / Cambridge, Massachusetts, United Statescrunchbase.com ↗

Ownership: Private
Development stage: Clinical

Overview

SciFluor developed a pipeline based on proprietary fluorine chemistry to create differentiated small molecule drugs. Lead programs included SF0034 for epilepsy/tinnitus and SF0166 for retinal diseases. As of the last available updates, SF0166 had entered clinical trials for AMD/DME, while SF0034 was advancing toward the clinic with strong preclinical data. No recent clinical results are available.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

SF0034

Preclinical

Beyond the preview

Go deeper on SciFluor Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciFluor Life Sciences.

Explore the full profile